KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 214 filers reported holding JUNO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.99 and the average weighting 0.9%.

Quarter-by-quarter ownership
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q4 2017$1,852,000
+2.0%
40,510
+0.1%
0.02%
-6.2%
Q3 2017$1,815,00040,4530.02%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q3 2017
NameSharesValueWeighting ↓
Biomark Capital Management Co. LLC 2,168,601$65,080,00086.12%
Crestline Management, LP 17,348,799$520,637,00066.02%
Omega Fund Management, LLC 1,229,512$36,898,00028.17%
SIB LLC 100,000$3,001,0002.42%
Clarius Group, LLC 117,896$3,538,0001.65%
BB BIOTECH AG 1,405,000$42,164,0001.48%
Duquesne Family Office 493,000$14,795,0001.31%
First Washington CORP 65,320$1,960,0001.10%
PFM Health Sciences, LP 1,124,285$33,740,0000.99%
Partner Investment Management, L.P. 18,376$551,0000.82%
View complete list of JUNO THERAPEUTICS INC shareholders